Results 91 to 100 of about 3,281 (174)

Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531)

, 2009
Patients with Immune thrombocytopenic purpura (ITP) often require immunoglobulin (Ig) therapy with intravenous 19 (IVIG) or anti-D to prevent or treat the serious bleeding events.
Pullarkat, Vinod A., Gernsheirner, Terry B., de Wolf, Joost Th. M., Stewart, Ron, Newland, Adrian, Wasser, Jeffrey S., Guthrie, Troy H., Berger, Dietmar, Stewart, Ron; id_orcid   +8 more
core   +1 more source

Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia

Background Chemotherapy-induced thrombocytopenia (CIT) is a common complication of chemotherapy that is associated with bleeding, reduced relative dose intensity, and potentially worse outcomes. No widely available therapies are approved for CIT. Methods
González Astorga, Beatriz, Geredeli, Caglayan, Munoz, Cesar, Korantzis, Ippokratis, Astorga, Beatriz Gonzalez, Al-Samkari, Hanny, Soff, Gerald A., Arslan, Cagatay   +7 more
core   +1 more source

Efficacy and safety of Romiplostim N01 for grades II to IV cancer therapy induced thrombocytopenia in a real world observational study

Discover Oncology
Objective To assess the clinical efficacy and safety of Romiplostim N01 for moderate-to-severe Cancer Therapy-Induced Thrombocytopenia (Grade II–IV, CTIT) in a real-world study.
Chi Zhang, Jun zhu xu, Yue Huang, Ying Cai, Jian-Guo Zhou, Hu Ma   +5 more
doaj   +1 more source

Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales [PDF]

, 2016
Objective: To evaluate the cost-effectiveness of eltrombopag compared with romiplostim as a treatment for chronic immune thrombocytopenia (cITP) in patients who are splenectomized or ineligible for splenectomy and are treatment refractory in England and ...
Grotzinger, Kelly, Bryden, Peter, Woods, Bethan Sarah, Allen, Rachel, Stapelkamp, Ceilidh   +4 more
core  

Real-world romiplostim dosing, response and home administration in paediatric immune thrombocytopenia. [PDF]

Br J Haematol
Harris EM, Montcrieff C, Grace RF.
europepmc   +1 more source

Severe Immune Thrombocytopenia Associated With Newly Diagnosed Rheumatoid Arthritis and Complicated by a Spontaneous Presacral Haematoma: A Case Report. [PDF]

Cureus
Win NS, Chit WO.
europepmc   +1 more source

Cost-effectiveness analysis of eltrombopag, hetrombopag and romiplostim for second-line treatment of primary immune thrombocytopenia in China. [PDF]

Front Med (Lausanne)
Chen X, Liu Y, Zhang J, Xu R, Guo C.
europepmc   +1 more source

Romiplostim for cancer treatment-induced thrombocytopenia in acute promyelocytic leukemia: a case report. [PDF]

Front Oncol
Yuan X, Guo Q, Zhang Z.
europepmc   +1 more source

A Review of Thrombopoietin Receptor Agonists and Subsequent Development of Thrombosis: Exploring a Hematologic Paradox. [PDF]

Cureus
Graifman G, Parekh R, C P RV, Nair A.
europepmc   +1 more source

Transient ST-segment elevation following coronary artery bypass grafting in a patient with immune thrombocytopenia treated with romiplostim: a case report. [PDF]

Egypt Heart J
Ansari ZR, Hamdulay ZA, Khan A, Jain S, Hamdulay M, Kothawala A.   +5 more
europepmc   +1 more source